Richard S. Houlston-Stefansson

London, ENG SW73RP, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 619 publications

Interpretation of Survival Outcomes in Multicancer Early Detection Testing Requires Caution.

Interpretation of Survival Outcomes in Multicancer Early Detection Testing Requires Caution.

Journal: JCO precision oncology

Published: June 17, 2026

Response to 'Impact of control selection strategies on GWAS results: a study of prostate cancer in the UK Biobank'.

Response to 'Impact of control selection strategies on GWAS results: a study of prostate cancer in the UK Biobank'.

Journal: Briefings in bioinformatics

Published: April 08, 2026

Re: Polygenic risk scores for pre-MRI risk stratification in men with clinically suspected prostate cancer.

Re: Polygenic risk scores for pre-MRI risk stratification in men with clinically suspected prostate cancer.

Journal: Journal of the National Cancer Institute

Published: March 17, 2026

Biological Drivers of IMiD-Induced Peripheral Neuropathy in Multiple Myeloma.

Biological Drivers of IMiD-Induced Peripheral Neuropathy in Multiple Myeloma.

Journal: EJHaem

Published: January 22, 2026

Clock-like mutational signatures: Linking ageing to endogenous cancer risk.

Clock-like mutational signatures: Linking ageing to endogenous cancer risk.

Journal: Ageing research reviews

Published: January 16, 2026

Moving beyond the neutral-Darwinian dichotomy to inform precision oncology.

Moving beyond the neutral-Darwinian dichotomy to inform precision oncology.

Journal: NPJ precision oncology

Published: January 05, 2026

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

Journal: The Lancet. Oncology

Published: December 03, 2025

Germline haploinsufficiency of MUTYH causes mutational signature SBS18 in multiple tumour types and specifically raises colorectal cancer risk.

Germline haploinsufficiency of MUTYH causes mutational signature SBS18 in multiple tumour types and specifically raises colorectal cancer risk.

Journal: NPJ precision oncology

Published: November 20, 2025

Media coverage and PATHFINDER2: hype, simplification, and free advertising.

Media coverage and PATHFINDER2: hype, simplification, and free advertising.

Journal: The Lancet. Oncology

Published: November 06, 2025

Promises under pressure: the modest predictive power of polygenic risk scores.

Promises under pressure: the modest predictive power of polygenic risk scores.

Journal: European journal of human genetics : EJHG

Published: October 28, 2025

Impact of surveillance colonoscopy on colorectal cancer incidence and mortality in Lynch syndrome: a national observational cohort study of patients in the English NHS 2010-2022.

Impact of surveillance colonoscopy on colorectal cancer incidence and mortality in Lynch syndrome: a national observational cohort study of patients in the English NHS 2010-2022.

Journal: Gut

Published: October 23, 2025

Colonoscopy surveillance in Lynch syndrome: what it prevents and what it does not.

Colonoscopy surveillance in Lynch syndrome: what it prevents and what it does not.

Journal: Journal of medical genetics

Published: October 20, 2025

Showing 1-12 of 619

Last Updated: 09/26/2026